In a landmark stride toward enhancing gene therapy, scientists from the Children’s Medical Research Institute (CMRI) have unveiled a revolutionary method for evaluating adeno-associated viral vector-based (AAV) gene therapies using whole human liver explants. This pioneering approach, leaded by Dr. Leszek Lisowski, the head of CMRI’s translational vectorology unit and the communicating author of the publication, utilizes an ex situ normothermic perfusion system. Detailed in Nature Communications, this innovation marks a critical step forward in developing clinically predictive model systems, crucial for the advancement of personalized medicine.
This research tackles the inherent complexities of liver-directed gene therapies by testing a suite of fourteen natural and bioengineered AAV vectors directly within human livers, under conditions both with and without neutralizing human sera. The standout performers, AAV-SYD12 and AAV-LK03, demonstrated superior cellular uptake and transgene expression under non-neutralizing conditions.
However, the study also shed light on the challenge posed by anti-AAV neutralizing antibodies, which extensively neutralized vectors of human origin, like those derived from AAV2/AAV3b, highlighting the efficiency of AAV8-derived variants.
Originating from a collaborative effort between CMRI’s translational vectorology research unit and a team at Royal Prince Alfred Hospital, this innovative approach addresses the limitations of traditional preclinical models in replicating human physiological conditions and predicting clinical outcomes. By directly assessing gene therapeutic function in the target organ, this model not only paves the way for more accurate dose estimation and side effect identification but also opens new avenues for the development of liver-focused gene therapies, potentially revolutionizing treatment strategies for various inherited diseases.
Cabanes-Creus, M., Liao, S.H.Y., Gale Navarro, R. et al. Harnessing whole human liver ex situ normothermic perfusion for preclinical AAV vector evaluation. Nat Commun 15, 1876 (2024). https://doi.org/10.1038/s41467-024-46194-y
https://www.nature.com/articles/s41467-024-46194-y
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Sangamo Therapeutics Secures Accelerated Approval Pathway for Gene Therapy in Fabry Disease
Sangamo Therapeutics has announced a major advancement in its gene therapy program for Fabry disease, as the U.S. FDA has provided a clear pathway for Accelerated Approval. This decision could potentially speed up approval timelines by three years, with a Biologics...
[2024/10/18] Gene and Cell Therapy- weekly digest from PackGene
FeaturedNewsArticlesPackGene's NewsletterReceive the latest news and insights to your inbox.About PackGenePackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span...
GSK sues Moderna over mRNA vaccine patents, seeks ‘reasonable royalty’
GSK on Tuesday unveiled a lawsuit filed against Moderna in Delaware federal court, alleging that its patented inventions provide the “foundation” for Moderna’s mRNA vaccine portfolio. GSK said it’s looking to recover “a reasonable royalty” for Moderna’s tens of...
Gene Therapy Automatically Converts Omega-6 to Omega-3 Fatty Acids in the Body
Shriners Children's Develops New Technology to Prevent Childhood Obesity ST. LOUIS, Oct. 16, 2024 /PRNewswire/ -- According to the Centers for Disease Control, nearly 20% of children and teens are considered obese. Research shows it can have a dramatic impact on a...
Related Services